Nutritional Interventions to Prevent and Treat Osteoarthritis. Part II: Focus on Micronutrients and Supportive Nutraceuticals

PM and R

Volumn 4, Issue 5 SUPPL., 2012, Pages

  Lopez, Hector L ^a  

^a The Center for Applied Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BORON; CALCITRIOL; CAPSAICIN; CHONDROITIN; CHONDROITIN SULFATE; COLECALCIFEROL; COLLAGEN TYPE 2; CURCUMIN; DIMETHYL SULFONE; DOCOSAHEXAENOIC ACID; FLAVOCOXID; FLAVONOID; GAMMA LINOLENIC ACID; GLUCOSAMINE; HYALURONIC ACID; ICOSAPENTAENOIC ACID; NAPROXEN; NICOTINAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; NUTRACEUTICAL; PIASCLEDINE; RESVERATROL; RETINOL; S ADENOSYLMETHIONINE; SELENIUM; TRACE ELEMENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D;

ARTHRALGIA; CLINICAL EFFECTIVENESS; DRUG MEGADOSE; FRUIT; HIP OSTEOARTHRITIS; HUMAN; JOINT STIFFNESS; KNEE OSTEOARTHRITIS; KNEE PAIN; NONHUMAN; NUT; NUTRIENT; NUTRITION; OSTEOARTHRITIS; OXIDATIVE STRESS; PAIN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SPICE; TEA; VEGETABLE; VITAMIN D DEFICIENCY; VITAMIN K DEFICIENCY; VITAMIN SUPPLEMENTATION;

ANIMALS; CATECHIN; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; DRUG COMBINATIONS; EPIGENESIS, GENETIC; HARPAGOPHYTUM; HUMANS; HYALURONIC ACID; MICRONUTRIENTS; OSTEOARTHRITIS; OXIDATIVE STRESS; PEPTIDE HYDROLASES; PROTEOMICS; S-ADENOSYLMETHIONINE; VISCOSUPPLEMENTS; VITAMINS;

EID: 84861356304     PISSN: 19341482     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmrj.2012.02.023     Document Type: Review

References (164)

1. Zhang W., Nuki G., Moskowitz R.W., et al. OARSI recommendations for the management of hip and knee osteoarthritis: Part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage 2010, 18:476-499.
2. Roddy E., Doherty M. Guidelines for management of osteoarthritis published by the American College of Rheumatology and the European League Against Rheumatism: Why are they so different?. Rheum Dis Clin North Am 2003, 29:717-731.
3. Hasan M., Shuckett R. Clinical features and pathogenetic mechanisms of osteoarthritis of the hip and knee. B C Med J 2010, 52:393-398.
4. Henrotin Y., Lambert C., Couchourel D., Ripoll C., Chiotelli E. Nutraceuticals: Do they represent a new era in the management of osteoarthritis?. A narrative review from the lessons taken with five products. Osteoarthritis Cartilage 2011, 19:1-21.
5. van den Berg W.B. Osteoarthritis year 2010 in review: Pathomechanisms. Osteoarthritis Cartilage 2011, 19:338-341.
6. Rennie K.L., Hughes J., Lang R., Jebb S.A. Nutritional management of rheumatoid arthritis: A review of the evidence. J Hum Nutr Diet 2003, 16:97-109.
7. Mollenhauer J.A., Erdmann S. Introduction: Molecular and biomechanical basis of osteoarthritis. Cell Mol Life Sci 2002, 59:3-4.
8. Ames B.N. Micronutrients prevent cancer and delay aging. Toxicol Lett 1998, 102(103):5-18.
9. Ames B.N., Atamna H., Killilea D.W. Mineral and vitamin deficiencies can accelerate the mitochondrial decay of aging. Mol Aspects Med 2005, 26:363-378.
10. Wang Y., Prentice L.F., Vitetta L., Wluka A.E., Cicuttini F.M. The effect of nutritional supplements on osteoarthritis. Altern Med Rev 2004, 9:275-296.
11. Jerosch J. Effects of glucosamine and chondroitin sulfate on cartilage metabolism in OA: Outlook on other nutrient partners especially omega-3 fatty acids. Int J Rheumatol 2011, 969012:1-17.
12. Yudoh K., Nguyen V.T., Nakamura H., et al. Potential involvement of oxidative stress in cartilage senescence and development of osteoarthritis: Oxidative stress induces chondrocyte telomere instability and downregulation of chondrocyte function. Arthritis Res Ther 2005, 7:R380-R391.
13. Altindag O., Erel O., Aksoy N., et al. Increased oxidative stress and its relation with collagen metabolism in knee osteoarthritis. Rheumatol Int 2007, 27:339-344.
14. Kotani K., Sakane N., Kamimoto M., Taniguchi N. Levels of reactive oxygen metabolites in patients with knee osteoarthritis. Australas J Ageing 2011, 30:231-233.
15. Clark A.G., Rohrbaugh A.L., Otterness I., Kraus V.B. The effects of ascorbic acid on cartilage metabolism in guinea pig articular cartilage explants. Matrix Biol 2002, 21:175-184.
16. Surapaneni K.M., Venkataramana G. Status of lipid peroxidation, glutathione, ascorbic acid, vitamin E and antioxidant enzymes in patients with osteoarthritis. Indian J Med Sci 2007, 61:9-14.
17. McAlindon T.E., Jacques P., Zhang Y., et al. Do antioxidant micronutrients protect against the development and progression of knee osteoarthritis?. Arthritis Rheum 1996, 39:648-656.
18. Moreno L.A., Valtueña J., Pérez-López F., González-Gross M. Health effects related to low vitamin D concentrations: Beyond bone metabolism. Ann Nutr Metab 2011, 59:22-27.
19. van Schoor N.M., Lips P. Worldwide vitamin D status. Best Pract Res Clin Endocrinol Metab 2011, 25:671-680.
20. Tetlow L.C., Woolley D.E. Expression of vitamin D receptors and matrix metalloproteinases in osteoarthritic cartilage and human articular chondrocytes in vitro. Osteoarthritis Cartilage 2001, 9:423-431.
21. Laragione T., Shah A., Gulko P.S. The vitamin d receptor regulates rheumatoid arthritis synovial fibroblast invasion and morphology. Mol Med 2011; Nov 2, [Epub ahead of print]. 10.2119/molmed.2011.00410.
22. Felson D.T., Niu J., Clancy M., et al. Low levels of vitamin D and worsening of knee osteoarthritis: Results of two longitudinal studies. Arthritis Rheum 2007, 56:129-136.
23. McAlindon T.E., Felson D.T., Zhang Y., et al. Relation of dietary intake and serum levels of vitamin D to progression of osteoarthritis of the knee among participants in the Framingham Study. Ann Intern Med 1996, 125:353-359.
24. Muraki S., Dennison E., Jameson K., et al. Association of vitamin D status with knee pain and radiographic knee osteoarthritis. Osteoarthritis Cartilage 2011, 19:1301-1306.
25. Heidari B., Heidari P., Hajian-Tilaki K. Association between serum vitamin D deficiency and knee osteoarthritis. Int Orthop 2011, 35:1627-1631.
26. Bansal A.S., Henriquez F., Sumar N., Patel S. T helper cell subsets in arthritis and the benefits of immunomodulation by 1,25(OH)(2) vitamin D. Rheumatol Int 2011 Sep 15, [Epub ahead of print].
27. Booth S.L., Suttie J.W. Dietary intake and adequacy of vitamin K. J Nutr 1998, 128:785-788.
28. Loeser R.F., Varnum B.C., Carlson C.S., et al. Human chondrocyte expression of growth-arrest-specific gene 6 and the tyrosine kinase receptor axl. Potential role in autocrine signaling in cartilage. Arthritis Rheum 1997, 40:1455-1465.
29. Newman B., Gigout L.I., Sudre L., Grant M.E., Wallis G.A. Coordinated expression of matrix Gla protein is required during endochondral ossification for chondrocyte survival. J Cell Biol 2001, 154:659-666.
30. Neogi T., Booth S.L., Zhang Y.Q., et al. Low vitamin K status is associated with osteoarthritis in the hand and knee. Arthritis Rheum 2006, 54:1255-1261.
31. Oka H., Akune T., Muraki S., et al. Association of low dietary vitamin K intake with radiographic knee osteoarthritis in the Japanese elderly population: Dietary survey in a population-based cohort of the ROAD study. J Orthop Sci 2009, 14:687-692.
32. Jonas W.B., Rapoza C.P., Blair W.F. The effect of niacinamide on osteoarthritis: A pilot study. Inflamm Res 1996, 45:330-334.
33. Kaufman W. The use of vitamin therapy to reverse certain concomitants of aging. J Am Geriatr Soc 1955, 3:927-936.
34. Miesel R., Kurpisz M., Kroger H. Modulation of inflammatory arthritis by inhibition of poly(ADP ribose) polymerase. Inflammation 1995, 19:379-387.
35. McCarty M.F., Russell A.L. Niacinamide therapy for osteoarthritis: Does it inhibit nitric oxide synthase induction by interleukin 1 in chondrocytes?. Med Hypoth 1999, 53:350-360.
36. Vieira A.T., Silveira K.D., Arruda M.C., et al. Treatment with Selemax®, a selenium-enriched yeast, ameliorates experimental arthritis in rats and mice. Br J Nutr 2012, 25:1-10.
37. Sasaki S., Iwata H., Ishiguro N., Habuchi O., Miura T. Low-selenium diet, bone, and articular cartilage in rats. Nutrition 1994, 10:538-543. 6.
38. Murad H., Tabibian P. The effect of an oral supplement containing glucosamine, amino acids, minerals, and antioxidants on cutaneous aging: A preliminary study. J Dermatol Treat 2001, 12:47-51.
39. Hill J., Bird H.A. Failure of selenium-ACE to improve osteoarthritis. Br J Rheumatol 1990, 29:211-213.
40. Newnham R.E. Essentiality of boron for healthy bones and joints. Environ Health Perspect 1994, 102(Suppl 7):83-85.
41. Helliwell T.R., Kelly S.A., Walsh H.P., et al. Elemental analysis of femoral bone from patients with fractured neck of femur or osteoarthrosis. Bone 1996, 18:151-157.
42. Emadi-Konjin P., Verjee Z., Levin A.V., Adeli K. Measurement of intracellular vitamin C levels in human lymphocytes by reverse phase high performance liquid chromatography (HPLC). Clin Biochem 2005, 38:450-456.
43. Miller E.R., Pastor-Barriuso R., Dalal D., et al. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005, 142:37-46.
44. Friedrich M.J. To "E" or not to "E," vitamin E's role in health and disease is the question. Jama 2004, 292:671-673.
45. Dietrich M., Traber M.G., Jacques P.F., et al. Does gamma-tocopherol play a role in the primary prevention of heart disease and cancer?. A review. J Am Coll Nutr 2006, 25:292-299.
46. Das S., Powell S.R., Wang P., et al. Cardioprotection with palm tocotrienol: Antioxidant activity of tocotrienol is linked with its ability to stabilize proteasomes. Am J Physiol Heart Circ Physiol 2005, 289:H361-H367.
47. Sen C., Khanna S., Roy S. Tocotrienols in health and disease: The other half of the natural vitamin E family. Mol Aspects Med 2007, 28:692-728.
48. Holick M.F., Binkley N.C., Bischoff-Ferrari H.A., et al. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011, 96:1911-1930. Endocrine Society.
49. Heaney R.P., Recker R.R., Grote J., Horst R.L., Armas L.A. Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab 2011, 96:E447-E452.
50. Pramyothin P., Holick M.F. Vitamin D supplementation: Guidelines and evidence for subclinical deficiency. Curr Opin Gastroenterol 2012, 28:139-150.
51. Martel-Pelletier J., Boileau C., Pelletier J.P., Roughley P.J. Cartilage in normal and osteoarthritis conditions. Best Pract Res Clin Rheumatol 2008, 22:351-384.
52. Kirkham S.G., Samarasinghe R.K. Review article: Glucosamine. J Orthop Surg (Hong Kong) 2009, 17:72-76.
53. Towheed T.E., Maxwell L., Anastassiades T.P., et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005, (2). CD002946.
54. Bruyere O., Pavelka K., Rovati L.C., et al. Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: Evidence from two 3-year studies. Menopause 2004, 11:138-143.
55. Richy F., Bruyere O., Ethgen O., et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: A comprehensive meta-analysis. Arch Intern Med 2003, 163:1514-1522.
56. Poolsup N., Suthisisang C., Channark P., Kittikulsuth W. Glucosamine long-term treatment and the progression of knee osteoarthritis: Systematic review of randomized controlled trials. Ann Pharmacother 2005, 39:1080-1087.
57. Bruyere O., Pavelka K., Rovati L.C., et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: Results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage 2008, 16:254-260.
58. Uebelhart D., Malaise M., Marcolongo R., et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: A one-year, randomized, double-blind, multicenter study versus placebo. Osteoarthritis Cartilage 2004, 12:269-276.
59. Kahan A., Uebelhart D., De Vathaire F., Delmas P.D., Reginster J.Y. Long-term effects of chondroitin sulfate on knee osteoarthritis: The study on osteoarthritis progression prevention, a two-year, randomized, double- blind, placebo-controlled trial. Arthritis Rheum 2009, 60:524-533.
60. Michel B.A., Stucki G., Frey D., et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: A randomized, controlled trial. Arthritis Rheum 2005, 52:779-786.
61. Jackson C.G., Plaas A.H., Sandy J.D., et al. The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. Osteoarthritis Cartilage 2010, 19:297-302.
62. Meulyzer M., Vachon P., Beaudry F., et al. Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride. Osteoarthritis Cartilage 2008, 16:973-979.
63. Gruenwald J., Petzold E., Busch R., Petzold H.P., Graubaum H.J. Effect of glucosamine sulfate with or without omega-3 fatty acids in patients with osteoarthritis. Adv Ther 2009, 26:858-871.
64. Moreland L.W. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: Mechanism of action. Arthritis Res Ther 2003, 5:54-67.
65. Maneiro E., de Andres M.C., Ferández-Sueiro J.L., Galdo F., Blanco F.J. The biological action of hyaluronan on human osteoarthritic articular chondrocytes: The importance of molecular weight. Clin Exp Rheumatol 2004, 22:307-312.
66. Adams M.E., Lussier A.J., Peyron J.G. A risk-benefit assessment of injections of hyaluronan and its derivatives in the treatment of knee osteoarthritis. Drug Saf 2000, 23:115-130.
67. Balogh L., Polyak A., Matheetal D. Absorption, uptake and tissue affinity of high-molecular-weight hyaluronan after oral administration in rats and dogs. J Agric Food Chem 2008, 56:10582-10593.
68. Kalman D.S., Heimer M., Valdeon A., Schwartz H., Sheldon E. Effect of a natural extract of chicken combs with a high content of hyaluronic acid (Hyal-Joint) on pain relief and quality of life in subjects with knee osteoarthritis: A pilot randomized double-blind placebo-controlled trial. Nutr J 2008, 7:1-9.
69. Henrotin Y.E., Labasse A.H., Jaspar J.M., et al. Effects of three avocado/soybean unsaponifiable mixtures on metalloproteinases, cytokines and prostaglandin E2 production by human articular chondrocytes. Clin Rheumatol 1998, 17:31-39.
70. Mauviel A., Daireaux M., Hartmann D.J., et al. Effects of unsaponifiable extracts of avocado/soy beans (PIAS) on the production of collagen by cultures of synovio- cytes, articular chondrocytes and skin fibroblasts. Rev Rhum Mal Osteoartic 1989, 56:207-211.
71. Henrotin Y.E., Sanchez C., Deberg M.A., et al. Avocado/soybean unsaponifiables increase aggrecan synthesis and reduce catabolic and proinflammatory mediator production by human osteoarthritic chondrocytes. J Rheumatol 2003, 30:1825-1834.
72. Blotman F., Maheu E., Wulwik A., Caspard H., Lopez A. Efficacy and safety of avocado/soybean unsaponifiables in the treatment of symptomatic osteoarthritis of the knee and hip. A prospective, multicenter, three-month, randomized, double-blind, placebo-controlled trial. Rev Rhum Engl Ed 1997, 64:825-834.
73. Appelboom T., Schuermans J., Verbruggen G., Henrotin Y., Reginster J.Y. Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis. A double blind, prospective, placebo-controlled study. Scand J Rheumatol 2001, 30:242-247.
74. Maheu E., Mazieres B., Valat J.P., et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: A prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month followup demonstrating a persistent effect. Arthritis Rheum 1998, 41:81-91.
75. Rizzo R., Grandolfo M., Godeas C., Jones K.W., Vittur F. Calcium, sulfur, and zinc distribution in normal and arthritic articular equine cartilage: A synchrotron radiation-induced X-ray emission (SRIXE) study. J Exp Zool 1995, 273:82-86.
76. Murav'ev IuV., Venikova M.S., Pleskovskaia G.N., Riazantseva T.A., Sigidin IaA. Effect of dimethyl sulfoxide and dimethyl sulfone on a destructive process in the joints of mice with spontaneous arthritis [in Russian with English abstract]. Patol Fiziol Eksp Ter 1991, 2:37-39.
77. Usha P.R., Naidu M.U.R. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Investig 2004, 24:353-363.
78. Kim L.S., Axelrod L.J., Howard P., Buratovich N., Waters R.F. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: A pilot clinical trial. Osteoarthritis Cartilage 2006, 14:286-294.
79. Debbi E.M., Agar G., Fichman G., et al. Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: A randomized controlled study. BMC Complement Altern Med 2011, 11:50.
80. Lieber C.S., Packer L. S-adenosylmethionine: Molecular, biological, and clinical aspects: An introduction. Am J Clin Nutr 2002, 76:1148S-1150S.
81. Barceló H.A., Wiemeyer J.C., Sagasta C.L., Macías M., Barreira J.C. Experimental osteoarthritis and its course when treated with S-adenosyl-L-methionine [in Spanish with English abstract]. Rev Clin Esp 1990, 187:74-78.
82. Kalbhen D.A., Jansen G. Pharmacologic studies on the antidegenerative effect of ademetionine in experimental arthritis in animals. Arzneimittelforschung 1990, 40:1017-1021.
83. Glorioso S., Todesco S., Mazzi A., et al. Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis. Int J Clin Pharmacol Res 1985, 5:39-49.
84. Vetter G. Double-blind comparative clinical trial with S-adenosylmethionine and indomethacin in the treatment of osteoarthritis. Am J Med 1987, 83:78-80.
85. Maccagno A., Di Giorgio E.E., Caston O.L., Sagasta C.L. Double-blind controlled clinical trial of oral S-adenosylmethionine versus piroxicam in knee osteoarthritis. Am J Med 1987, 83:72-77.
86. Gupta R.C., Canerdy T.D., Lindley J., et al. Comparative therapeutic efficacy and safety of type-II collagen (UC-II®), glucosamine and chondroitin in arthritic dogs: Pain evaluation by ground force plate. J Anim Physiol Anim Nutr (Berl) 2011 May 30, [Epub ahead of print]. 10.1111/j.1439-0396.2011.01166.x.
87. Crowley D.C., Lau F.C., Sharma P., et al. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: A clinical trial. Int J Med Sci 2009, 6:312-321.
88. Barnett M.L., Kremer J.M., St Clair E.W., et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 1998, 41:290-297.
89. D'Altilio M., Peal A., Alvey M., et al. Therapeutic efficacy and safety of undenatured type II collagen singly or in combination with glucosamine and chondroitin in arthritic dogs. Toxicol Mech Methods 2007, 17:189-196.
90. Deparle L.A., Gupta R.C., Canerdy T.D., et al. Efficacy and safety of glycosylated undenatured type-II collagen (UC-II®) in therapy of arthritic dogs. J Vet Pharmacol Ther 2005, 28:385-390.
91. Zhu P., Li X.Y., Wang H.K., et al. Oral administration of type-II collagen peptide 250-270 suppresses specific cellular and humoral immune response in collagen-induced arthritis. Clin Immunol 2007, 122:75-84.
92. Park K.S., Park M.J., Cho M.L., et al. Type II collagen oral tolerance: Mechanism and role in collagen-induced arthritis and rheumatoid arthritis. Mod Rheumatol 2009, 19:581-589.
93. Oesser S., Seifert J. Stimulation of type II collagen biosynthesis and secretion in bovine chondrocytes cultured with degraded collagen. Cell Tissue Res 2003, 311:393-399.
94. Oesser S., Adam M., Babel W., Seifert J. Oral administration of (14)C labeled gelatin hydrolysate leads to an accumulation of radioactivity in cartilage of mice (C57/BL). J Nutr 1999, 129:1891-1895.
95. Moskowitz R.W. Role of collagen hydrolysate in bone and joint disease. Semin Arthritis Rheum 2000, 30:87-99.
96. Adam M. Therapy for osteoarthritis: Which effects have preparations of gelatin?. Therapiewoche 1991, 38:2456-2461.
97. Schauss A.G., Merkel D.J., Glaza S.M., et al. Acute and subchronic oral toxicity studies in rats of a hydrolyzed chicken sternal cartilage preparation. Food Chem Toxicol 2007, 45:315-321.
98. Visioli F., De La Lastra C.A., Andres-Lacueva C., et al. Polyphenols and human health: A prospectus. Crit Rev Food Sci Nutr 2011, 51:524-546.
99. Russo M., Spagnuolo C., Tedesco I., Bilotto S., Russo G.L. The flavonoid quercetin in disease prevention and therapy: Facts and fancies. Biochem Pharmacol 2012, 83:6-15.
100. Fraga C.G., Oteiza P.I. Dietary flavonoids: Role of (-)-epicatechin and related procyanidins in cell signaling. Free Radic Biol Med 2011, 51:813-823.
101. González R., Ballester I., López-Posadas R., et al. Effects of flavonoids and other polyphenols on inflammation. Crit Rev Food Sci Nutr 2011, 51:331-362.
102. O'Leary K.A., de Pascual-Tereasa S., Needs P.W., Bao Y.P., O'Brien N.M., Williamson G. Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription. Mutat Res 2004, 551:245-254.
103. Ahmed S. Green tea polyphenol epigallocatechin 3-gallate in arthritis: Progress and promise. Arthritis Res Ther 2010, 12:208.
104. Ahmed S., Wang N., Lalonde M., Goldberg V.M., Haqqi T.M. Green tea polyphenol epigallocatechin-3-gallate (EGCG) differentially inhibits interleukin-1 beta-induced expression of matrix metalloproteinase-1 and -13 in human chondrocytes. J Pharmacol Exp Ther 2004, 308:767-773.
105. Singh R., Ahmed S., Malemud C.J., Goldberg V.M., Haqqi T.M. Epigallocatechin-3-gallate selectively inhibits interleukin-1beta-induced activation of mitogen activated protein kinase subgroup c-Jun N-terminal kinase in human osteoarthritis chondrocytes. J Orthop Res 2003, 21:102-109.
106. Murakami A., Song M., Katsumata S., Uehara M., Suzuki K., Ohigashi H. Citrus nobiletin suppresses bone loss in ovariectomized ddY mice and collagen-induced arthritis in DBA/1J mice: Possible involvement of receptor activator of NF-kappaB ligand (RANKL)-induced osteoclastogenesis regulation. Biofactors 2007, 30:179-192.
107. Ishiwa J., Sato T., Mimaki Y., Sashida Y., Yano M., Ito A. A citrus flavonoid, nobiletin, suppresses production and gene expression of matrix metalloproteinase 9/gelatinase B in rabbit synovial fibroblasts. J Rheumatol 2000, 27:20-25.
108. Adhikari S., Tilak J.C., Devasagayam T.P. Free radical reactions of a naturally occurring flavone baicalein and possible mechanisms towards its membrane protective properties. Indian J Biochem Biophys 2011, 48:275-282.
109. Messina S., Bitto A., Aguennouz A.M., et al. Flavocoxid inhibits NF-kappaB, MAPKs and COX/5-LOX pathways and improves muscle function and morphology in mdx mice: A comparison study with methylprednisolone. Exp Neurol 2009, 220:349-358.
110. Tseng-Crank J., Sung S., Jia Q., et al. A medicinal plant extract of Scutellaria baicalensis and Acacia catechu reduced LPS-stimulated gene expression in immune cells: A comprehensive genomic study using QPCR, ELISA, and microarray. J Diet Suppl 2010, 7:253-272.
111. Belcaro G., Cesarone M.R., Errichi S., et al. Treatment of osteoarthritis with Pycnogenol. The SVOS (San Valentino Osteo-arthrosis Study). Evaluation of signs, symptoms, physical performance and vascular aspects. Phytother Res 2008, 22:518-523.
112. Cisár P., Jány R., Waczulíková I., et al. Effect of pine bark extract (Pycnogenol) on symptoms of knee osteoarthritis. Phytother Res 2008, 22:1087-1092.
113. Peng Y.J., Lee C.H., Wang C.C., Salter D.M., Lee H.S. Pycnogenol attenuates the inflammatory and nitrosative stress on joint inflammation induced by urate crystals. Free Radic Biol Med 2012, 52:765-774.
114. Cesarone M.R., Belcaro G., Rohdewald P., et al. Improvement of signs and symptoms of chronic venous insufficiency and microangiopathy with Pycnogenol: A prospective, controlled study. Phytomedicine 2010, 17:835-839.
115. Liu X., Wei J., Tan F., Zhou S., Würthwein G., Rohdewald P. Antidiabetic effect of Pycnogenol French maritime pine bark extract in patients with diabetes type II. Life Sci 2004, 75:2505-2513.
116. Enseleit F., Sudano I., Périat D., et al. Effects of pycnogenol on endothelial function in patients with stable coronary artery disease: A double-blind, randomized, placebo-controlled, cross-over study. Eur Heart J 2012 Jan 11, [Epub ahead of print].
117. Altavilla D., Squadrito F., Bitto A., et al. Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages. Br J Pharmacol 2009, 157:1410-1418.
118. Burnett B.P., Bitto A., Altavilla D., Squadrito F., Levy R.M., Pillai L. Flavocoxid inhibits phospholipase A2, peroxidase moieties of the cyclooxygenases (COX), and 5-lipoxygenase, modifies COX-2 gene expression, and acts as an antioxidant. Mediators Inflamm 2011, 2011:385780.
119. Levy R.M., Khokhlov A., Kopenkin S., et al. Efficacy and safety of flavocoxid, a novel therapeutic, compared with naproxen: A randomized multicenter controlled trial in subjects with osteoarthritis of the knee. Adv Ther 2010, 27:731-742.
120. Levy R.M., Saikovsky R., Shmidt E., Khokhlov A., Burnett B.P. Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: A short-term randomized, double-blind pilot study. Nutr Res 2009, 29:298-304.
121. Pillai L., Burnett B.P., Levy R.M. GOAL: Multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin. Curr Med Res Opin 2010, 26:1055-1063. GOAL Study Cooperative Group.
122. Pillai L., Levy R.M., Yimam M., Zhao Y., Jia Q., Burnett B.P. Flavocoxid, an anti-inflammatory agent of botanical origin, does not affect coagulation or interact with anticoagulation therapies. Adv Ther 2010, 27:400-411.
123. Morgan S.L., Baggott J.E., Moreland L., Desmond R., Kendrach A.C. The safety of flavocoxid, a medical food, in the dietary management of knee osteoarthritis. J Med Food 2009, 12:1143-1148.
124. Gottlieb D., Kuritzky L. Using the medical food flavocoxid in managing osteoarthritis. J Pain Palliat Care Pharmacother 2011, 25:49-54.
125. Adcocks C., Collin P., Buttle D.J. Catechins from green tea (Camellia sinensis) inhibit bovine and human cartilage proteoglycan and type II collagen degradation in vitro. J Nutr 2002, 132:341-346.
126. Tsubata M., Takagaki K., Hirano S., Iwatani K., Abe C. Effects of flavangenol, an extract of French maritime pine bark on collagen-induced arthritis in rats. J Nutr Sci Vitaminol 2011, 57:251-257.
127. Hwang S.L., Shih P.H., Yen G.C. Neuroprotective effects of citrus flavonoids. J Agric Food Chem 2012, 60:877-885.
128. Obrenovich M.E., Nair N.G., Beyaz A., Aliev G., Reddy V.P. The role of polyphenolic antioxidants in health, disease, and aging. Rejuvenation Res 2010, 13:631-643.
129. Banerjee M., Tripathi L.M., Srivastava V.M., Puri A., Shukla R. Modulation of inflammatory mediators by ibuprofen and curcumin treatment during chronic inflammation in rat. Immunopharmacol Immunotoxicol 2003, 25:213-224.
130. Hong J., Bose M., Ju J., et al. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: Effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 2004, 25:1671-1679.
131. Shakibaei M., John T., Schulze-Tanzil G., Lehmann I., Mobasheri A. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclooxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: Implications for the treatment of osteoarthritis. Biochem Pharmacol 2007, 73:1434-1445.
132. Joe B., Lokesh B.R. Effect of curcumin and capsaicin on arachidonic acid metabolism and lysosomal enzyme secretion by rat peritoneal macrophages. Lipids 1997, 32:1173-1180.
133. Shakibaei M., Mobasheri A., Buhrmann C. Curcumin synergizes with resveratrol to stimulate the MAPK signaling pathway in human articular chondrocytes in vitro. Genes Nutr 2011, 6:171-179.
134. Kuptniratsaikul V., Thanakhumtorn S., Chinswangwatanakul P., Wattanamongkonsil L., Thamlikitkul V. Efficacy and safety of Curcuma domestica extracts in patients with knee osteoarthritis. J Altern Complement Med 2009, 15:891-897.
135. Aggarwal B.B., Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 2006, 71:1397-1421.
136. Shukla P.K., Khanna V.K., Ali M.M., Khan M.Y., Srimal R.C. Anti-ischemic effect of curcumin in rat brain. Neurochem Res 2008, 33:1036-1043.
137. Maheshwari R.K., Singh A.K., Gaddipati J., Srimal R.C. Multiple biological activities of curcumin: A short review. Life Sci 2006, 78:2081-2087.
138. Miriyala S., Panchatcharam M., Rengarajulu P. Cardioprotective effects of curcumin. Adv Exp Med Biol 2007, 595:359-377.
139. Saw C.L., Huang Y., Kong A.N. Synergistic anti-inflammatory effects of low doses of curcumin in combination with polyunsaturated fatty acids: Docosahexaenoic acid or eicosapentaenoic acid. Biochem Pharmacol 2010, 79:421-430.
140. Srivastava K.C., Mustafa T. Ginger (Zingiber officinale) in rheumatism and musculoskeletal disorders. Med Hypoth 1992, 39:342-348.
141. Frondoza C.G., Sohrabi A., Polotsky A., et al. An in vitro screening assay for inhibitors of proinflammatory mediators in herbal extracts using human synoviocyte cultures. In Vitro Cell Dev Biol Anim 2004, 40:95-101.
142. Altman R.D., Marcussen K.C. Effects of a ginger extract on knee pain in patients with osteoarthritis. Arthritis Rheum 2001, 44:2531-2538.
143. Schulze-Tanzil G., de S.P., Behnke B., Klingelhoefer S., Scheid A., Shakibaei M. Effects of the antirheumatic remedy hox alpha: A new stinging nettle leaf extraction matrix metalloproteinases in human chondrocytes in vitro. Histol Histopathol 2002, 17:477-485.
144. Obertreis B., Ruttkowski T., Teucher T., Behnke B., Schmitz H. Ex-vivo in-vitro inhibition of lipopolysaccharide stimulated tumor necrosis factor-alpha and interleukin-1 beta secretion in human whole blood by extractum urticae dioicae foliorum. Arzneimittelforschung 1996, 46:389-394.
145. Jacquet A., Girodet P.O., Pariente A., Forest K., Mallet L., Moore N. Phytalgic, a food supplement, vs placebo in patients with osteoarthritis of the knee or hip: A randomised double-blind placebo-controlled clinical trial. Arthritis Res Ther 2009, 11:R192-R201.
146. Schulze-Tanzil G., Hansen C., Shakibaei M. Effect of a Harpagophytum procumbens DC extract on matrix metalloproteinases in human chondrocytes in vitro. Arzneimittelforschung 2004, 54:213-220.
147. Fiebich B.L., Muñoz E., Rose T., Weiss G., McGregor G.P. Molecular targets of the anti-inflammatory Harpagophytum procumbens (Devil's claw): Inhibition of TNFα and COX-2 gene expression by preventing activation of AP-1. Phytother Res 2011, 10:36-45.
148. Gagnier J.J., Chrubasik S., Manheimer E. Harpagophytum procumbens for osteoarthritis and low back pain: A systematic review. BMC Complement Altern Med 2004, 4:13-23.
149. Wegener T., Lupke N.P. Treatment of patients with arthrosis of hip or knee with an aqueous extract of devil's claw (Harpagophytum procumbens DC). Phytother Res 2003, 17:1165-1172.
150. Sailer E.R., Subramanian L.R., Rall B., Hoernlein R.F., Ammon H.P., Safayhi H. Acetyl-11-keto-beta-boswellic acid (AKBA): Structure requirements for binding and 5-lipoxygenase inhibitory activity. Br J Pharmacol 1996, 117:615-618.
151. Abdel-Tawab M., Werz O., Schubert-Zsilavecz M. Boswellia serrata: An overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinet 2011, 50:349-369.
152. Kimmatkar N., Thawani V., Hingorani L., Khiyani R. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee: A randomized double blind placebo controlled trial. Phytomedicine 2003, 10:3-7.
153. Badria F.A., El-Farahaty T., Shabana A.A., Hawas S.A., El-Batoty M.F. Boswellia-curcumin preparation for treating knee osteoarthritis. Altern Complement Ther 2002, 8:341-348.
154. Kulkarni R.R., Patki P.S., Jog V.P., Gandage S.G., Patwardhan B. Treatment of osteoarthritis with a herbomineral formulation: A double-blind, placebo-controlled, cross-over study. J Ethnopharmacol 1991, 33:91-95.
155. Brien S., Lewith G., Walker A., Hicks S.M., Middleton D. Bromelain as a treatment for osteoarthritis: A review of clinical studies. Evid Based Complement Altern Med 2004, 1:251-257.
156. Tilwe G.H., Beria S., Turakhia N.H., Daftary G.V., Schiess W. Efficacy and tolerability of oral enzyme therapy as compared to diclofenac in active osteoarthrosis of knee joint: An open randomized controlled clinical trial. J Assoc Physicians India 2001, 49:617-621.
157. Klein G., Kullich W. Short-term treatment of painful osteoarthritis of the knee with oral enzymes. Clin Drug Invest 2000, 19:15-23.
158. Singer F., Oberleitner H. Drug therapy of activated arthrosis. On the effectiveness of an enzyme mixture versus diclofenac. Wien Med Wochenschr 1996, 146:55-58.
159. Mandel D.R., Eichas K., Holmes J. Bacillus coagulans: A viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complement Altern Med 2010, 10:1.
160. Amdekar S., Singh V., Singh R., Sharma P., Keshav P., Kumar A. Lactobacillus casei reduces the inflammatory joint damage associated with collagen-induced arthritis (CIA) by reducing the pro-inflammatory cytokines: Lactobacillus casei: COX-2 inhibitor. J Clin Immunol 2011, 31:147-154.
161. So J.S., Lee C.G., Kwon H.K., et al. Lactobacillus casei potentiates induction of oral tolerance in experimental arthritis. Mol Immunol 2008, 46:172-180.
162. Parisuthiman D., Singhatanadgit W., Dechatiwongse T., Koontongkaew S. Cissus quadrangularis extract enhances biomineralization through up-regulation of MAPK-dependent alkaline phosphatase activity in osteoblasts. In Vitro Cell Dev Biol Anim 2009, 45:194-200.
163. Potu B.K., Bhat K.M., Rao M.S., et al. Petroleum ether extract of Cissus quadrangularis (Linn) enhances bone marrow mesenchymal stem cell proliferation and facilitates osteoblastogenesis. Clinics (São Paulo) 2009, 64:993-998.
164. Kong J.S., Yoo S.A., Kim H.S., et al. Inhibition of synovial hyperplasia, rheumatoid T cell activation, and experimental arthritis in mice by sulforaphane, a naturally occurring isothiocyanate. Arthritis Rheum 2010, 62:159-170.